Pitfalls in efficacy testing – how important is the validation of neutralization of chlorhexidine digluconate?

Por Reichel, Mirja, Heisig, Peter, Kampf, Günter
Publicado em 2008

Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects

Por Wiedemann, Bernd, Heisig, Anke, Heisig, Peter
Publicado no Antibiotics (Basel) (2014)

Modelling and management of engineering processes

Por Heisig, Peter., Clarkson, P. John., Vajna, Sandor.
Publicado em 2010

Impact of gyrA and parC Mutations on Quinolone Resistance, Doubling Time, and Supercoiling Degree of Escherichia coli

Por Bagel, Simone, Hüllen, Volker, Wiedemann, Bernd, Heisig, Peter
Publicado em 1999

Alcohols for Skin Antisepsis at Clinically Relevant Skin Sites

Por Reichel, Mirja, Heisig, Peter, Kohlmann, Thomas, Kampf, Günter
Publicado em 2009

In Vivo Increase in Resistance to Ciprofloxacin in Escherichia coli Associated with Deletion of the C-Terminal Part of MarR

Por Linde, Hans-Jörg, Notka, Frank, Metz, Michaela, Kochanowski, Bernd, Heisig, Peter, Lehn, Norbert
Publicado em 2000

Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfoprist...

Por Jones, Mark E., Visser, Maarten R., Klootwijk, Miriam, Heisig, Peter, Verhoef, Jan, Schmitz, Franz-Josef
Publicado em 1999

Resistance to Moxifloxacin in Toxigenic Clostridium difficile Isolates Is Associated with Mutations in gyrA

Por Ackermann, Grit, Tang, Yajarayma J., Kueper, Robert, Heisig, Peter, Rodloff, Arne C., Silva, Joseph, Cohen, Stuart H.
Publicado em 2001

A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II

Por Gruger, Thomas, Nitiss, John L., Maxwell, Anthony, Zechiedrich, E. Lynn, Heisig, Peter, Seeber, Siegfried, Pommier, Yves, Strumberg, Dirk
Publicado em 2004

Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating fr...

Por Jones, Mark E., Sahm, Daniel F., Martin, Nele, Scheuring, Sibylle, Heisig, Peter, Thornsberry, Clyde, Köhrer, Karl, Schmitz, Franz-Josef
Publicado em 2000

Association of Alterations in ParC and GyrA Proteins with Resistance of Clinical Isolates of Enterococcus faecium to Nine Different Fluoroquinolones

Por Brisse, Sylvain, Fluit, Ad C., Wagner, Ulrich, Heisig, Peter, Milatovic, Dana, Verhoef, Jan, Scheuring, Sybille, Köhrer, Karl, Schmitz, Franz-Josef
Publicado em 1999

In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus

Por Boos, Mechthild, Mayer, Susanne, Fischer, Ansgar, Köhrer, Karl, Scheuring, Sibylle, Heisig, Peter, Verhoef, Jan, Fluit, Ad C., Schmitz, F.-J.
Publicado em 2001

In Vitro Activities of Fluoroquinolones against the Spirochete Borrelia burgdorferi

Por Kraiczy, Peter, Weigand, Judith, Wichelhaus, Thomas A., Heisig, Peter, Backes, Herbert, Schäfer, Volker, Acker, Georg, Brade, Volker, Hunfeld, Klaus-Peter
Publicado em 2001

Commonality among Fluoroquinolone-Resistant Sequence Type ST131 Extraintestinal Escherichia coli Isolates from Humans and Companion Animals in Australia

Por Platell, Joanne L., Cobbold, Rowland N., Johnson, James R., Heisig, Anke, Heisig, Peter, Clabots, Connie, Kuskowski, Michael A., Trott, Darren J.
Publicado em 2011

Prominence of an O75 Clonal Group (Clonal Complex 14) among Non-ST131 Fluoroquinolone-Resistant Escherichia coli Causing Extraintestinal Infections in Humans and Dogs in Australia

Por Platell, Joanne L., Trott, Darren J., Johnson, James R., Heisig, Peter, Heisig, Anke, Clabots, Connie R., Johnston, Brian, Cobbold, Rowland N.
Publicado em 2012